Immuneering is a biopharmaceutical company that develops medicines for the treatment of a spectrum of oncologic diseases. Its pipeline includes IMM-1-104 that aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, as well as IMM-6-415, a deep cyclic inhibitor of the mitogen-activated protein kinase pathway.